Neukam, KarinMunteanu, Daniela IRivero-Juárez, AntonioLutz, ThomasFehr, JanMandorfer, MattiasBhagani, SanjayLópez-Cortés, Luis FHaberl, AnnetteStoeckle, MarcelMárquez, ManuelScholten, Stefande Los Santos-Gil, IgnacioMauss, StefanRivero, AntonioCollado, AntonioDelgado, MarcialRockstroh, Juergen KPineda, Juan A2016-09-122016-09-122015-04-29Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, et al. Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PLoS ONE. 2015; 10(4):e0125080http://hdl.handle.net/10668/2407Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND AND AIMS Clinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alone. This study sought to evaluate the efficacy and safety of triple therapy including BOC or TVR in combination with PR in HIV/HCV-coinfected patients under real-life conditions. METHODS In a multicentre study conducted in 24 sites throughout five European countries, all HIV/HCV-coinfected patients who initiated a combination of BOC or TVR plus PR and who had at least 60 weeks of follow-up, were analyzed. Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated. RESULTS Of the 159 subjects included, 127 (79.9%) were male, 45 (34.4%) were treatment-naïve for PR and 60 (45.4%) showed cirrhosis. SVR12 was observed in 31/46 (67.4%) patients treated with BOC and 69/113 (61.1%) patients treated with TVR. Overall discontinuations due to AE rates were 8.7% for BOC and 8% for TVR. Grade 3 or 4 hematological abnormalities were frequently observed; anemia 7%, thrombocytopenia 17.2% and neutropenia 16.4%. CONCLUSION The efficacy and safety of triple therapy including BOC or TVR plus PR under real-life conditions of use in the HIV/HCV-coinfected population was similar to what is observed in clinical trials. Hematological side effects are frequent but manageable.enCoinfecciónEuropaFemeninoVIHAdultoHepacivirusInfecciones por VIHHepatitis C crónicaHumanosMasculinoMediana edadOligopéptidosProlinaRivavirinaResultado del tratamientoMedical Subject Headings::Diseases::Virus Diseases::CoinfectionMedical Subject Headings::Geographicals::Geographic Locations::EuropeMedical Subject Headings::Check Tags::FemaleMedical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIVMedical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV InfectionsMedical Subject Headings::Organisms::Viruses::Hepatitis Viruses::HepacivirusMedical Subject Headings::Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, ChronicMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Check Tags::MaleMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle AgedMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::OligopeptidesMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Imino Acids::ProlineMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::RibavirinMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment OutcomeMedical Subject Headings::Named Groups::Persons::Age Groups::Adultresearch article25923540open access10.1371/journal.pone.01250801932-6203PMC4414348